148 related articles for article (PubMed ID: 31441728)
1. Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
Arowosegbe MA; Amusan OT; Adeola SA; Adu OB; Akinola IA; Ogungbe BF; Omotuyi OI; Saibu GM; Ogunleye AJ; Kanmodi RI; Lugbe NE; Ogunmola OJ; Ajayi DC; Ogun SO; Oyende FO; Bello AO; Ishola PG; Obasieke PE
Curr Drug Discov Technol; 2020; 17(5):682-695. PubMed ID: 31441728
[TBL] [Abstract][Full Text] [Related]
2. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
[TBL] [Abstract][Full Text] [Related]
3. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
[TBL] [Abstract][Full Text] [Related]
4. In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation.
Gao Y; Wang H; Wang J; Cheng M
J Biomol Struct Dyn; 2020 Sep; 38(14):4119-4133. PubMed ID: 31556340
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2,4-diaminopyrimidine derivatives targeting p21-activated kinase 4: Biological evaluation and docking studies.
Qin Q; Wu T; Yin W; Sun Y; Zhang X; Wang R; Guo J; Zhao D; Cheng M
Arch Pharm (Weinheim); 2020 Oct; 353(10):e2000097. PubMed ID: 32627873
[TBL] [Abstract][Full Text] [Related]
6. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
[TBL] [Abstract][Full Text] [Related]
7. Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study.
Guo J; Zhu M; Wu T; Hao C; Wang K; Yan Z; Huang W; Wang J; Zhao D; Cheng M
Bioorg Med Chem; 2017 Jul; 25(13):3500-3511. PubMed ID: 28502459
[TBL] [Abstract][Full Text] [Related]
8. Computational insight into p21-activated kinase 4 inhibition: a combined ligand- and structure-based approach.
Li RJ; Wang J; Xu Z; Huang WX; Li J; Jin SF; Zhao DM; Cheng MS
ChemMedChem; 2014 May; 9(5):1012-22. PubMed ID: 24643945
[TBL] [Abstract][Full Text] [Related]
9. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
10. Kaempferol ameliorates the regulatory effects of
Huang J; Chen Z; Lai Z; Liu Y; Yu D; Wu L; Zhou X
Future Med Chem; 2021 Apr; 13(7):613-623. PubMed ID: 33527844
[No Abstract] [Full Text] [Related]
11. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
12. Development of 2, 4-diaminoquinazoline derivatives as potent PAK4 inhibitors by the core refinement strategy.
Hao C; Huang W; Li X; Guo J; Chen M; Yan Z; Wang K; Jiang X; Song S; Wang J; Zhao D; Li F; Cheng M
Eur J Med Chem; 2017 May; 131():1-13. PubMed ID: 28284095
[TBL] [Abstract][Full Text] [Related]
13. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
[TBL] [Abstract][Full Text] [Related]
14. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study.
Sinha S; Patel S; Athar M; Vora J; Chhabria MT; Jha PC; Shrivastava N
Int J Biol Macromol; 2019 Nov; 140():454-468. PubMed ID: 31404596
[TBL] [Abstract][Full Text] [Related]
15. Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation.
Su Y; Song P; Wang H; Hu B; Wang J; Cheng MS
J Biomol Struct Dyn; 2020 Aug; 38(13):3825-3837. PubMed ID: 31490101
[TBL] [Abstract][Full Text] [Related]
16. In silico molecular docking and physicochemical property studies on effective phytochemicals targeting GPR116 for breast cancer treatment.
Muthiah I; Rajendran K; Dhanaraj P
Mol Cell Biochem; 2021 Feb; 476(2):883-896. PubMed ID: 33106912
[TBL] [Abstract][Full Text] [Related]
17. Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
Sharma A; Sinha S; Rathaur P; Vora J; Jha PC; Johar K; Rawal RM; Shrivastava N
Mol Divers; 2022 Dec; 26(6):3337-3356. PubMed ID: 35147860
[TBL] [Abstract][Full Text] [Related]
18. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity.
Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS
Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553
[TBL] [Abstract][Full Text] [Related]
19. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
[TBL] [Abstract][Full Text] [Related]
20. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
